I keep going back to the Phase 2 result: 24.2% mean weight reduction at 48 weeks under the efficacy estimand. Then company-reported Phase 3 says up to 28.7%, not peer-reviewed yet. Those aren’t apples to apples, right?
I’ve also been staring at CTgov: NCT05882045 enrolled 1946, NCT05929066 enrolled 2335, knee OA 445, postmenopausal 46, Chinese cohort 32. A few are completed but no headline results in the raw record. What’s the useful way to compare these without overreading press releases?
I’m less interested in hype than figuring out what the actual endpoint definitions and populations are doing.